Home / Tag Archives: Guselkumab

Tag Archives: Guselkumab

Guselkumab front and center at EADV Congress

edav dermatology conference

Due to the combination of efficacy, safety, and convenience, the interleukin (IL)-23 inhibitors will represent a “significant broadening” of the therapeutic armamentarium for moderate-to-severe psoriasis, according to Prof. Dr. Kristian Reich of Dermatologikum Hamburg in Hamburg, Germany. Dr. Reich spoke on how IL-23 inhibitors fit into the psoriasis treatment armamentarium in a special melanoma session here …

Read More »